Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LLY
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
LLY
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

LLY Price Prediction Next Week

Based on the provided data and recent market activity, here's the analysis and price prediction for LLY for the next trading week:

Technical Analysis

  • LLY closed at $725.72 on Friday, January 17, down 4.21%
  • The stock has formed a bearish trend with significant selling pressure, breaking below key support levels
  • RSI at 35.08 indicates oversold conditions but not yet at extreme levels
  • MACD shows bearish momentum with -11.44 reading

News Sentiment Analysis

  • Negative catalyst: LLY lowered 2024 revenue guidance to $45 billion, below previous guidance of $45.4-46 billion
  • Positive catalyst: Strong demand continues for key drugs Mounjaro and Zepbound, with combined Q4 sales of $5.4 billion
  • FDA approval for Zepbound to treat sleep apnea in December 2024 could boost demand
  • Upcoming oral weight-loss pill orforglipron expected for approval in early 2026

Price Prediction for Next Week Based on technical and fundamental factors:

Target Prices:

  • Support level: $702.47
  • Resistance level: $748.97
  • Expected trading range: $702-749 with high probability

Trading Recommendation: SELL with following reasons:

  1. Breaking below key support levels with increased volume
  2. Negative momentum indicators and bearish trend continuation pattern
  3. Lower guidance creating near-term selling pressure
  4. Stock expected to test support at $702 level before potential stabilization

Price targets:

  • Short-term (1 week): $685-705 range with 70% probability
  • Key level to watch: $744.91 - if price breaks above this level, bearish thesis invalidated

The stock is showing clear technical weakness and fundamental headwinds in the short term, suggesting further downside potential in the coming week.

Based on the provided data and recent market activity, here's the analysis and price prediction for LLY for the next trading week:

Technical Analysis

  • LLY closed at $725.72 on Friday, January 17, down 4.21%
  • The stock has formed a bearish trend with significant selling pressure, breaking below key support levels
  • RSI at 35.08 indicates oversold conditions but not yet at extreme levels
  • MACD shows bearish momentum with -11.44 reading

News Sentiment Analysis

  • Negative catalyst: LLY lowered 2024 revenue guidance to $45 billion, below previous guidance of $45.4-46 billion
  • Positive catalyst: Strong demand continues for key drugs Mounjaro and Zepbound, with combined Q4 sales of $5.4 billion
  • FDA approval for Zepbound to treat sleep apnea in December 2024 could boost demand
  • Upcoming oral weight-loss pill orforglipron expected for approval in early 2026

Price Prediction for Next Week Based on technical and fundamental factors:

Target Prices:

  • Support level: $702.47
  • Resistance level: $748.97
  • Expected trading range: $702-749 with high probability

Trading Recommendation: SELL with following reasons:

  1. Breaking below key support levels with increased volume
  2. Negative momentum indicators and bearish trend continuation pattern
  3. Lower guidance creating near-term selling pressure
  4. Stock expected to test support at $702 level before potential stabilization

Price targets:

  • Short-term (1 week): $685-705 range with 70% probability
  • Key level to watch: $744.91 - if price breaks above this level, bearish thesis invalidated

The stock is showing clear technical weakness and fundamental headwinds in the short term, suggesting further downside potential in the coming week.

LLY Similar Chart Price Prediction

The price of LLY is predicted to go up 12.72%, based on the high correlation periods with LMND. The similarity of these two price pattern on the periods is 92.06%.

stocks logo

LLY

stocks logo

LMND

Up: 12.72%Similarity: 92.06%

LLY Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030

Year

LLY Price Forecast($)

Potential Return(%)

2025

787.140

0.660

2026

950.000

21.490

2027

1,200.000

53.460

2028

1,200.000

53.460

2029

1,200.000

56.840

2030

1,200.000

56.840

What is LLY stock price prediction 2025 ?

LLY stock is currently trading at $787.14. Based on its strong growth drivers, including high demand for Mounjaro and Zepbound, and expected revenue growth from new drug launches, the stock could reach $850-$900 by the end of 2025. However, risks such as regulatory challenges and competition in the weight-loss drug market may limit upside potential.

What is LLY stock price prediction 2026 ?

LLY stock is projected to reach $950 by 2026, driven by strong demand for its obesity and diabetes drugs, Mounjaro and Zepbound, alongside new product launches and international market expansion. The company's robust pipeline and innovation in key therapeutic areas like Alzheimer's and oncology further support this growth. However, potential risks include regulatory challenges and competition in the weight-loss drug market.

What is LLY stock price prediction 2027 ?

LLY stock is projected to reach approximately $1,200 by 2027, driven by strong growth in its obesity and diabetes drugs, Mounjaro and Zepbound, and expansion into Alzheimer's and oncology markets. The company's robust pipeline, strategic acquisitions, and increasing global demand for its innovative treatments support this valuation. However, competition and regulatory risks remain key challenges.

What is LLY stock price prediction 2028 ?

LLY stock is projected to reach approximately $1,200 by 2028, driven by its dominance in the weight loss and diabetes drug market, particularly with Mounjaro and Zepbound. The obesity drug market is expected to grow significantly, and Eli Lilly's strong pipeline and strategic investments in manufacturing capacity position it well for sustained revenue growth. Additionally, its expansion into Alzheimer's and immunology markets further supports long-term valuation growth.

What is LLY stock price prediction 2029 ?

The price prediction for Eli Lilly (LLY) stock in 2029 is approximately $1,200, driven by its dominance in the weight-loss drug market, expanding GLP-1 applications, and robust R&D investments. The obesity drug market is projected to grow significantly, with LLY maintaining a strong competitive edge through innovation and manufacturing capacity. Additionally, its diversification into Alzheimer's and immunology markets supports long-term growth potential.

What is LLY stock price prediction 2030 ?

LLY stock is projected to reach approximately $1,200 by 2030, driven by its leadership in the weight-loss and diabetes drug markets, particularly with Mounjaro and Zepbound. The company’s robust pipeline, strategic investments in manufacturing, and expansion into new therapeutic areas like Alzheimer’s and immunology further support long-term growth. However, competition from Novo Nordisk and potential market saturation could moderate gains.

LLY Revenue Forecast

LLY EPS Forecast

LLY FAQs

What is bull’s view on LLY?

Eli Lilly (LLY) is currently trading at $778.07, with analysts maintaining a bullish outlook due to its strong growth drivers like Mounjaro and Zepbound, which dominate the weight-loss and diabetes markets. Price targets range from $975 to $1,250, reflecting a potential upside of 25%-40%, driven by expanding international sales, pipeline innovations, and label expansions. Despite short-term inventory challenges, its robust R&D investments and market leadership position make it a compelling long-term hold.

What is bear's view on LLY?

LLY stock currently trades at $781.87, with bearish momentum indicated by its RSI of 47.02 and trading below key SMAs (50-day at $841.23 and 200-day at $838.29). The stock faces resistance near $803.78 (Fibonacci R1) and support at $758.74 (Fibonacci S1), suggesting limited upside in the short term. Concerns over valuation (Forward P/E of 59.16) and potential growth deceleration make it less favorable for bears.

What is LLY revenue forecast for next quarter？

The market consensus for LLY's revenue in the upcoming quarter is projected to be approximately $12.917B USD.

What is LLY eps forecast for next quarter？

The market consensus for LLY's eps in the upcoming quarter is projected to be approximately $4.954 USD.

LLY VS S&P500

Lilly's strong leadership in weight-loss drugs should drive industry-leading growth with approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.

Lilly's cancer drug Verzenio reported strong data in early-stage breast cancer, opening up the strong potential in this multi-billion-dollar market.

Lilly is developing a new Alzheimer's drug (donanemab) that could become a major blockbuster, especially because the FDA appears to have a lower threshold for approval for this disease.

Ask Intellectia about LLY

LLY Analyst's Forecast

Tim Anderson

B of A Securities

Strong Buy

Price Target

$997

Upside

+24.69%

BofA analyst Tim Anderson reinstated coverage of Eli Lilly with a Buy rating and $997 price target. Eli Lilly is "likely to see bouts of volatility" on obesity-related news flow, but should be a core long-term holding due to its outsized, durable long-term growth and many "protective moats," the analyst tells investors.
Carter Gould

Barclays

Buy

Price Target

$1,025 → $975

Upside

+17.47%

Geoff Meacham

B of A Securities

Strong Buy

Price Target

$1,150 → $1,100

Upside

+32.53%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2024 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free